Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is als...
Altamira Therapeutics reported revenue of $0 for fiscal year 2024, and net income of -$8.46 million. Its market capitalization was $314,350 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
No profile data available.